The Interministerial Commission of drug prices by the Ministry of Health, Social Affairs and Equal public funding has been authorized by the National Health System (NHS) of the first drug approved in Spain derived from cannabis, which Almirall marketed under the name Sativex .

This drug, which was authorized by the Spanish Agency for Medicines and Medical Devices (AEMPS) last July 2010, is indicated for the treatment of spasticity in multiple sclerosis.

According to the Interministerial Commission has agreed, its use is restricted to the diagnosis and delivery in hospital, and prescription and visa required inspection.

So far, it was used under the compassionate use system in the absence of deciding its incorporation to the public provision of the NHS and set a price. Finally, the drug will cost about 440 euros, of which the NHS will take over when used as authorized